High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 9, 2014, Pages 624-632

  Stenkvist, Jenny ^a,b   Weiland, Ola ^a,b   Sönnerborg, Anders ^a   Blaxhult, Anders ^a   Falconer, Karolin ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HCV treatment uptake; HIV HCV co infection

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; COHORT ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PHYSICIAN; PREVALENCE; QUESTIONNAIRE; SWEDEN; TREATMENT OUTCOME; ADOLESCENT; AGED; COINFECTION; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; PATIENT ATTITUDE; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; SWEDEN; YOUNG ADULT;

EID: 84906277786     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2014.921932     Document Type: Article

References (37)

1. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012; 142: 1324-34.e3.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
3. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
4. Alter M J. Epidemiology of viral hepatitis and HIV co-infection . J Hepat 2006; 44(1 Suppl): S6-9.
5. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008; 13:pii 18888.
6. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61(Suppl 1): i47-58.
7. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
8. Lifson AR, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, et al. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008; 9: 177-85.
9. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. J Hepat 2009; 50: 736-45.
10. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009; 10: 282-9.
11. Gill J, May M, Lewden C, Saag M, Mugavero M, Reiss P, et al.; Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.
12. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-48.
13. Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection 2011; 39: 13-20.
14. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14: 195-207.
15. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57: 249-57.
16. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepat 2003; 38: 257-65.
17. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-91.
18. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-8.
19. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
20. Mira JA, Rivero-Juarez A, Lopez-Cortes LF, Giron-Gonzalez JA, Tellez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56: 1646-53.
21. Fleming C A. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97-100.
22. Rauch A. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon- alpha plus ribavirin. J Acquir Immune Defic Syndr 2005; 38: 238-40.
23. Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006; 38: 1092-7.
24. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral Ther 2006; 11: 131-42.
25. Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003; 36: 1039-46.
26. Grebely J, Bryant J, Hull P, Hopwood M, Lavis Y, Dore GJ, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18: e104-16.
27. Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-36.
28. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010; 153: 231-9.
29. Stenkvist J, Nyström J, Falconer K, Sönnerborg A, Weiland O. Spontaneous clearance or chronic evolution of HCV in HIV/HCV co-infected patients - influence of the IL28B genotype. J Hepatol 2013; 58(Suppl): S204.
30. Lidman C, Norden L, Kaberg M, Kall K, Franck J, Aleman S, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009; 41: 679-84.
31. van der Helm JJ, Prins M, del Amo J, Bucher HC, Chene G, Dorrucci M, et al. The hepatitis C epidemic among HIVpositive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25: 1083-91.
32. Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM? Curr Opin Infect Dis 2013; 26: 66-72.
33. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis 2013; 56: 1480-7.
34. Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol 2005; 34: 108-14.
35. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIVinfected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 1337-44.
36. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, et al. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA . HIV Med 2013; 14: 614-23.
37. Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviethsdottir L, Hultcrantz R, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat 2011; 18: 106-18.